NewHydrogen, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NewHydrogen, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.27M) | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | ($482.1K) | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | ($623.7K) | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | ($476.1K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($462.8K) | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | ($438.7K) | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | ($437.4K) | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | ($471.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($443.8K) | Mar 25, 2025 |
| FY2024 | Sep 30, 2023 | ($440.6K) | Mar 25, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.85M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.81M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($3.18M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($12.09M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($52.45M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($629.8K) | May 20, 2022 |
| FY2020 | Dec 31, 2019 | ($700.2K) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($699.5K) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($1.85M) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($2.33M) | Mar 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $615.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $362.5K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $202.9K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.10M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.22M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $177.7K | May 20, 2022 |
| FY2020 | Dec 31, 2019 | $264.7K | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $239.6K | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $176.3K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $226.9K | Mar 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.99M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.57M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($1.16M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.81M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($2.08M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($647.3K) | May 20, 2022 |
| FY2020 | Dec 31, 2019 | ($718.4K) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($631.0K) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($560.5K) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($671.9K) | Mar 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $5.8K | Mar 9, 2020 |
| FY2017 | Dec 31, 2016 | $2.6K | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $759 | Mar 17, 2017 |
| FY2015 | Dec 31, 2014 | $844 | Mar 4, 2016 |
| FY2013 | Dec 31, 2013 | $81.8K | Mar 24, 2014 |
| FY2013 | Dec 31, 2012 | $2.6K | Mar 24, 2014 |
| FY2011 | Dec 31, 2011 | $79.2K | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $2.6K | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.46M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.13M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.71M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.87M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $6.69M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $155.1K | May 20, 2022 |
| FY2020 | Dec 31, 2019 | $132.3K | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $153.3K | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $219.0K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $317.5K | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.8K | May 20, 2022 |
| FY2021 | Dec 31, 2020 | $152.07M | May 20, 2022 |
| FY2020 | Dec 31, 2019 | $12.35M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $17.15M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $7.87M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $6.96M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $9.10M | Mar 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.04M) | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | ($2.15M) | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | ($2.32M) | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | ($1.78M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.36M) | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | ($955.8K) | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | ($572.0K) | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | ($177.6K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $217.1K | Mar 30, 2026 |
| FY2024 | Sep 30, 2023 | $594.6K | Mar 25, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($180.79M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($177.94M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($176.13M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($172.96M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($160.87M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($165.08M) | May 20, 2022 |
| FY2020 | Dec 31, 2019 | ($24.53M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($28.65M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($18.79M) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($16.00M) | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.10M | Mar 25, 2025 |
| FY2024 | Dec 31, 2023 | $3.68M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.83M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $6.65M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $63.5K | May 20, 2022 |
| FY2020 | Dec 31, 2019 | $61.8K | Feb 16, 2021 |
| FY2020 | Dec 31, 2018 | $82.7K | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $119.4K | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $208.6K | Mar 21, 2019 |
| FY2017 | Dec 31, 2015 | $202.6K | Mar 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.60M | Mar 9, 2020 |
| FY2019 | Dec 31, 2018 | $2.47M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.79M | Mar 21, 2019 |
| FY2020 | Dec 31, 2008 | $2.76M | Feb 16, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | May 20, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | May 20, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 768.03M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 704.60M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 704.60M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 715.50M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 715.50M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 456.20M | May 20, 2022 |
| FY2020 | Dec 31, 2019 | 133.91M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 60.64M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 41.49M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 29.52M | Mar 20, 2018 |